Vivos Therapeutics, FDA
The gross proceeds to the Company from the offering are expected to be approximately $4.3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The ...
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related ...
Vivos Therapeutics shares rose on Wednesday after the company said its oral medical device for pediatric sleep apnea and snoring received 510(k) clearance from the Food and Drug Administration.
The function is not a diagnostic tool, but can tell watch-wearers if they are exhibiting signs of sleep apnea.
What a session it was for a certain Colorado-based %Healthcare company after it was announced that it received the US Food ...
Apple announced that pending FDA approval, recent versions of the company's popular smartwatches will soon get features that ...
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos' DNA appliance ...